BioProcess International’s Post

Our panel discussion is now live!

Conquering Potency Testing Challenges in Therapeutics Development with iLite® Technology Potency testing is a critical aspect of therapeutic development, ensuring the effectiveness and safety of pharmaceutical products. While cell-based assays are highly recommended for their accuracy in potency testing, customizing them to target specific compounds can be a complex process. Our principal partner, Svar Life Science, with iLite® Technology has engineered an advanced solution to overcome these challenges. Leveraging their expertise in cell engineering and proven technology, we have developed a range of customized potency assays designed specifically for complex antibodies and other challenging targets. Their innovative approach not only streamlines the potency testing process but also drives advancements in gene therapy and other cutting-edge therapeutic areas. iLite® cell-based technology is a pioneering approach to developing potency assays for a wide range of complex antibody therapeutics. From tri-specific monoclonal antibodies to AAV-encoded transgenes and neutralizing antibody assays, iLite® technology offers versatile and precise solutions that are essential in therapeutic development. Svar Life Science AB Nour Adilien Martin Sjunnesson Eva-Christina Ahlgren Hannes Brehm Filiz Ibraimi Itzia Ferrer, PhD #lifescience #biotechnology #pharamaceutics #cell #cellbasedassay #therapeutics #antibodies #genetherapy #neutralizingantibody #ilitetechnology #dualreporterassay #monoclonalantibody #drugdiscovery #svarlifescience #btlbiotechnolabspvtltd

Join us for an informative #BPIAskTheExpert webinar with BioProcess International, where we will explore upstream process intensification. This session is a must-attend for anyone looking to maximize their mAbs, cell therapy, or gene therapy manufacturing. Charles Hill, field applications scientist from Repligen will discuss how the XCell® ATF System and KrosFlo® TFDF® System revolutionize upstream applications, offering real-world case studies on increasing productivity and reducing costs. Webinar Title: More Product Faster: Maximize mAbs, Cell Therapy, and Gene Therapy Production with Upstream Process Intensification Date: July 25, 2024 Time: 11 am EDT | 8 am PDT | 5 pm CEST Duration: 30 minutes Key Takeaways: * Achieve 2-10x higher titers with the XCell ATF System. * Accelerate speed to market with ATF and TFDF technology. * Learn about scaling from process development to commercial manufacturing. Don't miss out on this opportunity to enhance your production capabilities. Register now and spread the word to your network! https://lnkd.in/gyGHX8ib #KrosFloTFDF, #N-1seedtrain,#lentivirus, #Viralvector, #Perfusion, #Genetherapy #XCellATF #IntensificationStartsHere #ProcessIntensification #UpstreamBioprocessing #bioproduction #processdevelopment #cellculture #bioprocessing #CDMO #biomanufacturing #celltherapy #biologics #antibodies #biosimilars

Conquer Potency Testing Challenges in Therapeutics Development with iLite® Technology. Cell-based assays are recommended for accurate potency testing, yet adapting them to specific targets can be complex. Our advanced cell engineering expertise and proven technology overcome these hurdles, creating tailored potency assays for complex antibodies and driving gene therapy advancements. Join a community driving breakthroughs in therapeutics development! Download this Editorial Article and discover how iLite® Technology can redefine your approach to development: https://hubs.ly/Q02sFDM90 #TherapeuticsDevelopment #PotencyTesting #Bioassays #CellEngineering #iLiteTechnology #BiotechInnovation #AnswersinLifeScience #ExpertPartner #genetherapy #antibodies #iLite

Potency assays can be challenging for advanced biologics including viral vector-based therapies. In this whitepaper, learn about Catalent’s mRNA transcriptional assay and how it compares to other analytical methods used to assess potency for cell and gene therapies. https://ow.ly/GN7t50QphY1

Barcode Nanotech - We are happy to be featured in "Pioneers of Promise: Top 40 in Gene Delivery". This review highlights the promise of LNP technology in RNA delivery including successful clinical outcomes and future prospects. Barcode Nanotech has demonstrated that its proprietary nanoparticles selectively lead RNA to the liver and to ex-liver target such as lungs, spleen and tumors. Continuing to excel, we are now developing our own RNA therapeutics while we optimize additional LNPs, targeting even more ex-liver targets such as kidney, CNS and selective immune cells. We are expecting promising results with our constantly growing list of collaborators which now include some of the world's largest pharma and biotech companies. https://lnkd.in/eEeUxbAd

Potency assays can be challenging for advanced biologics including viral vector-based therapies. In this whitepaper, learn about Catalent’s mRNA transcriptional assay and how it compares to other analytical methods used to assess potency for cell and gene therapies. https://ow.ly/GN7t50QphY1

bluebird bio Inc (NASDAQ:BLUE), the gene therapy developer, is well-positioned to outperform pessimistic expectations regarding the launch of its Lyfgenia treatment. Shares fell close to 70% in December, and analysts at Baird believe much of the negative sentiment surrounding the stock is due to disappointment by the lack of Lyfgenia cell collections. In a regulatory filing from December, bluebird said it expects to see 85 to 105 patients initiate the treatment process across its three approved cell therapies Lyfgenia, Zynteglo, and Skysona in 2024. While the number of cell collections has disappointed some investors, Baird notes that for patients to begin cell collection they must wait two months minimum to wash out any existing sickle cell therapies. More at #Proactive #ProactiveInvestors #NASDAQ #BLUE http://ow.ly/YZ8A105nwSP

I get excited when fantastic technology makes it to market, especially therapeutics where the hurdles can sometimes seem vast, endless or insurmountable. Vertex Pharmaceuticals and CRISPR Therapeutics CRISPR-based gene editing therapy, exa-cel, could imminently become the first CRISPR-based gene editing therapy approved by the FDA. A recent meeting of the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee assessed and seemed satisfied with potential off-target effects. An FDA decision on exa-cel in sickle cell disease is due by December 8, 2023. Vertex are preparing for launch and managing expectations for 2024 to be a "foundational year" (see article below for more). I hope this is the first of many therapies using this ground-breaking technology to make it from clinic to patient. #CRISPR #genetherapy #lifesciences #patents https://lnkd.in/eqGNYScv

Collaboration and sharing of expertise between BD and Cell and Gene Therapy Catapult has helped to provide developers of advanced medicinal cell products with key insights on how to optimise their flow cytometry workflows and accelerate product development. Personally, I thoroughly enjoyed this opportunity to collaborate with experts in the field, share knowledge and then make this knowledge widely available. Read the whitepaper: https://lnkd.in/e7qC_tcn #CellTherapy #GeneTherapy #ATMPs #AdvancedTherapies #Tcells #BD #bectondickinson #flowcytometry